#1 Clinical Trials Search in Europe

OLVEREMBATINIB

Olverembatinib (also known as HQP1351) is a novel third-generation tyrosine kinase inhibitor (TKI) that shows promise in treating various blood cancers, particularly those with the Philadelphia chromosome. This drug is currently being investigated in multiple clinical trials across different conditions, including chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and other rare blood disorders. Olverembatinib has shown effectiveness against resistant forms of these diseases, including those with the challenging T315I mutation that makes them resistant to earlier-generation TKIs. This article explores the current clinical trials evaluating olverembatinib’s efficacy, safety, and potential combinations with other therapies.

Table of Contents

What is Olverembatinib?

Olverembatinib (also known as HQP1351) is a novel third-generation tyrosine kinase inhibitor (TKI) designed to target a variety of blood cancers[1]. It was developed by Ascentage Pharma and has already received approval in China for treating certain types of leukemia[1]. Olverembatinib is particularly important because it can effectively target a spectrum of BCR-ABL mutations, including the difficult-to-treat T315I mutation, which often causes resistance to first and second-generation TKIs[1].

What Conditions Does Olverembatinib Treat?

Based on the clinical trials data, Olverembatinib is being studied for or already used in treating several conditions:

  • Chronic Myeloid Leukemia (CML) – particularly for patients in chronic phase (CP-CML) and accelerated phase (AP-CML) who have developed resistance to other tyrosine kinase inhibitors or who have the T315I mutation[2].
  • Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) – both for newly diagnosed patients and those with relapsed or refractory disease[3].
  • SDH-deficient Gastrointestinal Stromal Tumor (GIST) – for patients who have previously received at least one line of therapy[4].
  • Myeloid/Lymphoid Tumors with FGFR1 Rearrangement – which are rare hematologic malignancies with poor outcomes using conventional treatments[5].

How Does Olverembatinib Work?

Olverembatinib belongs to a class of medications called tyrosine kinase inhibitors (TKIs). It works by blocking the activity of abnormal proteins (specifically BCR-ABL tyrosine kinases) that signal cancer cells to multiply[2]. By inhibiting these proteins, Olverembatinib helps stop the growth and spread of cancer cells.

What makes Olverembatinib special is its ability to work against cancer cells that have developed a specific mutation called T315I, which makes them resistant to first and second-generation TKIs[1]. Additionally, Olverembatinib can inhibit many other kinases related to tumors and has shown synergistic effects when combined with other cancer treatments[5].

How is Olverembatinib Administered?

Based on the clinical trials information, Olverembatinib is typically:

  • Taken orally (by mouth) as tablets
  • Administered at a dose of 40mg every other day (QOD), though some trials are exploring different dosages (30mg QOD for newly diagnosed patients)[6]
  • Given with meals to improve absorption
  • Administered in 28-day cycles

Dosing may be adjusted based on individual patient factors, response to treatment, and side effects. Always follow your healthcare provider’s specific instructions regarding dosage and administration[4].

Efficacy of Olverembatinib

Clinical trials have shown promising results for Olverembatinib across several conditions:

  • For CML patients with resistance or intolerance to various TKIs, with or without T315I mutations, there are significant hematological and molecular responses and survival benefits[5].
  • For Ph+ ALL, when combined with other therapies such as blinatumomab or reduced-intensity chemotherapy, studies aim to achieve high rates of complete molecular remission (CMR)[7].
  • Multiple ongoing trials are evaluating combinations of Olverembatinib with other drugs like venetoclax and azacitidine for various leukemias[8].

The efficacy of Olverembatinib is typically measured by several parameters:

  • Major Molecular Response (MMR) – defined as BCR-ABL1 transcripts ≤ 0.1 percent[2].
  • Complete Molecular Response (CMR) – defined as the absence of detectable BCR-ABL1 transcripts with a sensitivity of 0.01%[9].
  • Progression-Free Survival (PFS) – the time from treatment start until disease progression or death[3].
  • Overall Survival (OS) – the time from treatment start until death from any cause[3].

Potential Side Effects

Like all medications, Olverembatinib may cause side effects. The clinical trials are closely monitoring these adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0[10].

While specific side effect profiles are still being fully established through ongoing clinical trials, patients should be aware of potential side effects that are common with TKIs:

  • Hematologic effects (affecting blood cells): anemia, decreased white blood cell counts, decreased platelet counts
  • Fatigue
  • Nausea
  • Diarrhea
  • Skin rash
  • Muscle cramps
  • Headache
  • Elevated liver enzymes

Your healthcare provider will monitor you closely for any side effects and may adjust your dose if necessary[2].

Ongoing Research and Future Applications

There is extensive ongoing research to expand the applications of Olverembatinib and explore combination therapies:

  • Combination therapies: Many trials are examining Olverembatinib in combination with other drugs such as venetoclax (a BCL-2 inhibitor), azacitidine (a hypomethylating agent), and blinatumomab (a bispecific T-cell engager)[8].
  • Post-transplant therapy: Some studies are exploring Olverembatinib as maintenance or preventive therapy after stem cell transplantation to reduce the risk of relapse[11].
  • Pediatric applications: Research is underway to determine the safety and efficacy of Olverembatinib in pediatric patients with Ph+ ALL[12].
  • Reduced chemotherapy approaches: Several trials are investigating “chemotherapy-light” regimens incorporating Olverembatinib to reduce the toxicity of traditional chemotherapy while maintaining or improving efficacy[12].

Current Clinical Trials

There are multiple ongoing clinical trials evaluating Olverembatinib across various conditions and treatment scenarios. Some notable studies include:

  • POLARIS-3: A study of Olverembatinib in SDH-deficient Gastrointestinal Stromal Tumor[4].
  • POLARIS-2: A global, multicenter study comparing Olverembatinib to bosutinib in patients with chronic phase CML[13].
  • Studies of Olverembatinib combined with blinatumomab for Ph+ ALL[3].
  • Studies exploring combinations of Olverembatinib with venetoclax and azacitidine for blast phase CML[8].
  • A Named Patient Program providing access to Olverembatinib in over 100 countries where the drug is not yet available[1].

If you’re interested in participating in a clinical trial, speak with your healthcare provider about whether you might be eligible for any ongoing studies of Olverembatinib for your specific condition.

Disease Type Key Clinical Trials Dosing Combination Therapies Key Outcomes Measured
Chronic Myeloid Leukemia (CML) NCT05311943, NCT06817720, NCT06423911, NCT05594758 Typically 40mg QOD in 28-day cycles; some studies use 30mg QOD Bosutinib (as comparator); Venetoclax + Azacitidine for blast phase Major Molecular Response (MMR), Complete Cytogenetic Response (CCyR), Overall Survival (OS), Progression-Free Survival (PFS)
Philadelphia Chromosome-positive ALL (Ph+ ALL) NCT05931757, NCT05466175, NCT06051409, NCT06220487, NCT05594784 40mg QOD, usually in 28-day cycles Blinatumomab, Venetoclax, Dexamethasone, Reduced-intensity chemotherapy, Chidamide Complete Molecular Response (CMR), Minimal Residual Disease (MRD) negativity, Event-Free Survival (EFS), Overall Survival (OS)
SDH-deficient GIST NCT06640361 40mg QOD with meals, 28-day cycles Used as monotherapy Progression-Free Survival (PFS) rate, Clinical Benefit Rate
FGFR1-rearranged Neoplasms NCT05521204 Not specified in available data Used with HSCT as consolidation Overall Response Rate, Event-Free Survival, Overall Survival
Pediatric Ph+ ALL NCT07152041, NCT05495035 Adult equivalent dose of 40mg QOD Blinatumomab, Venetoclax, Reduced-intensity chemotherapy MRD negativity rates, Day 48 MRD, Event-Free Survival
Post-transplantation Therapy NCT05604755, NCT06658925, NCT05603156 40mg QOD, with possible reduction to 30mg QOD Sometimes combined with Inotuzumab Ozogamicin for MRD persistence Disease-Free Survival, Relapse-Free Survival, MRD clearance rate

FAQ

  • What is Olverembatinib and how does it work? Olverembatinib (also known as HQP1351) is a novel third-generation tyrosine kinase inhibitor (TKI) that targets the BCR-ABL protein, which is created by the Philadelphia chromosome abnormality in certain blood cancers. It works by blocking the activity of this abnormal protein, which drives cancer cell growth. Olverembatinib is particularly effective against a spectrum of BCR-ABL mutations, including the T315I mutation that makes cancers resistant to first and second-generation TKIs. It's also being studied for its ability to inhibit other cancer-related kinases and potentially work synergistically with other medications.
  • What conditions is Olverembatinib being tested for in clinical trials? Olverembatinib is being tested in clinical trials for several blood cancers and conditions, including: chronic myeloid leukemia (CML) in chronic, accelerated, and blast phases; Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL); SDH-deficient gastrointestinal stromal tumor (GIST); and myeloid/lymphoid neoplasms with FGFR1 rearrangement. It's being evaluated both as a single agent and in combination with other therapies like venetoclax, blinatumomab, azacitidine, and various chemotherapy regimens.
  • What are the dosing patterns for Olverembatinib in clinical trials? In most clinical trials, Olverembatinib is administered orally at a dose of 40mg every other day (QOD) in 28-day cycles. It's generally taken with meals. Some studies adjust the dose to 30mg QOD for maintenance therapy once patients achieve complete molecular response. For pediatric patients, equivalent adult doses are calculated. The dosing schedule may vary when Olverembatinib is combined with other medications. Dose adjustments may be made based on individual patient response and tolerance.
  • What are the potential benefits of Olverembatinib over earlier-generation TKIs? Olverembatinib offers several potential advantages over earlier-generation TKIs. It can effectively target the T315I mutation and other BCR-ABL mutations that cause resistance to first and second-generation TKIs. Clinical studies indicate significant hematological and molecular responses in patients who have failed multiple prior TKI therapies. Additionally, it may have broader inhibitory effects on other cancer-related kinases. Olverembatinib is being studied in combination therapies that may provide synergistic effects, particularly in difficult-to-treat blood cancers, potentially offering new options for patients with limited treatment alternatives.
  • What side effects or safety concerns are being monitored in Olverembatinib trials? Clinical trials are closely monitoring the safety profile of Olverembatinib by assessing the incidence of adverse events according to standardized criteria (NCI CTCAE v5.0). Common measurements include the number of participants experiencing treatment-related adverse events, the severity of these events, and any serious adverse events. Specific attention is given to both hematologic toxicities (affecting blood cells) and non-hematologic toxicities. Several trials also examine pharmacokinetic profiles (how the drug moves through the body) and drug interactions. Long-term safety and the impact on quality of life are additional important safety considerations being evaluated.

Ongoing Clinical Trials on OLVEREMBATINIB

  • Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia France Hungary Italy Romania +1

  • Study of Olverembatinib and Bosutinib for Patients with Chronic Phase Chronic Myeloid Leukemia

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy Poland Spain

Glossary

  • Tyrosine Kinase Inhibitor (TKI): A class of drugs that block specific enzymes called tyrosine kinases, which are involved in cell signaling, growth, and division. In cancer treatment, TKIs target abnormal proteins that promote cancer cell growth.
  • Philadelphia Chromosome (Ph+): An abnormal chromosome formed when genetic material is exchanged between chromosomes 9 and 22, creating the BCR-ABL fusion gene that produces an abnormal protein driving certain types of leukemia.
  • Chronic Myeloid Leukemia (CML): A type of cancer that starts in certain blood-forming cells of the bone marrow. In CML, the bone marrow makes too many white blood cells. CML typically progresses slowly and has different phases: chronic phase (CP), accelerated phase (AP), and blast phase/crisis (BP/BC).
  • Acute Lymphoblastic Leukemia (ALL): A type of cancer in which the bone marrow makes too many immature lymphocytes (a type of white blood cell). Ph+ ALL refers to acute lymphoblastic leukemia with the Philadelphia chromosome.
  • T315I Mutation: A specific mutation in the BCR-ABL gene that makes leukemia cells resistant to most first and second-generation tyrosine kinase inhibitors. This mutation has been particularly challenging to treat.
  • Minimal Residual Disease (MRD): Small numbers of cancer cells that remain in the body during or after treatment. These cells are often below the level that can be detected by standard tests but can be found using more sensitive techniques.
  • Complete Molecular Response (CMR): The absence of detectable BCR-ABL transcripts in the blood or bone marrow, typically defined as BCR-ABL levels below 0.01% using sensitive testing methods.
  • Major Molecular Response (MMR): A reduction in the level of BCR-ABL transcripts to ≤0.1% as measured by standardized testing. This indicates the disease is well-controlled.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse. PFS is measured from the start of treatment until disease progression or death.
  • Cytogenetic Response: A measure of the proportion of cells with the Philadelphia chromosome. Complete Cytogenetic Response (CCyR) means no Ph+ cells are detected, while Partial Cytogenetic Response (PCyR) means 1-35% of cells are Ph+.
  • Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT): A procedure in which a patient receives blood-forming stem cells from a genetically similar, but not identical, donor. This is often used as a potentially curative treatment for various blood cancers.
  • GIST (Gastrointestinal Stromal Tumor): A type of tumor that usually begins in specialized cells in the wall of the gastrointestinal tract. SDH-deficient GIST refers to a specific subtype with a deficiency in succinate dehydrogenase.
  • Venetoclax: A medication that selectively targets the B-cell lymphoma 2 (BCL-2) protein, which helps cancer cells survive. It's being tested in combination with Olverembatinib in several clinical trials.
  • Blinatumomab: A bispecific T-cell engager (BiTE) antibody that connects CD3-positive T cells to CD19-positive B cells, helping the immune system destroy cancer cells. It's being studied in combination with Olverembatinib for Ph+ ALL.
  • Azacitidine: A hypomethylating agent that affects DNA and may restore normal function to genes that control cell growth and differentiation. It's being studied in combination with Olverembatinib for certain leukemias.
  • CAR-T Cell Therapy: A type of treatment in which a patient's T cells (a type of immune cell) are changed in the laboratory to attack cancer cells. Some trials are exploring Olverembatinib in combination with CAR-T therapy.
  • QOD: Medical abbreviation for 'every other day' dosing schedule, which is how Olverembatinib is typically administered in clinical trials.
  • CTCAE: Common Terminology Criteria for Adverse Events, a standardized system (version 5.0 is currently used) for classifying the severity of adverse events in clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT05594758
  2. https://clinicaltrials.gov/study/NCT05311943
  3. https://clinicaltrials.gov/study/NCT05931757
  4. https://clinicaltrials.gov/study/NCT06640361
  5. https://clinicaltrials.gov/study/NCT05521204
  6. https://clinicaltrials.gov/study/NCT06817720
  7. https://clinicaltrials.gov/study/NCT05594784
  8. https://clinicaltrials.gov/study/NCT06757855
  9. https://clinicaltrials.gov/study/NCT06220487
  10. https://clinicaltrials.eu/trial/study-of-olverembatinib-with-chemotherapy-versus-standard-therapy-in-adults-with-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/
  11. https://clinicaltrials.gov/study/NCT05604755
  12. https://clinicaltrials.gov/study/NCT07152041
  13. https://clinicaltrials.eu/trial/study-of-olverembatinib-and-bosutinib-for-patients-with-chronic-phase-chronic-myeloid-leukemia/